Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, Catherine A. Dennen, Eric R. Braverman, David Baron, Thomas Mclaughlin, John Giordano, Ashim Gupta, Bernard W. Downs, Debasis Bagchi, Debmalya Barh, Igor Elman, Panayotis K. Thanos, Rajendra D. Badgaiyan, Drew Edwards, Mark S. Gold
Research output: Contribution to journal › Review article › peer-review
2Scopus
citations
Fingerprint
Dive into the research topics of 'Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids'. Together they form a unique fingerprint.